{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:44:16Z","timestamp":1777866256148,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["Z01AI000947"],"award-info":[{"award-number":["Z01AI000947"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","award":["65252"],"award-info":[{"award-number":["65252"]}],"id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vaccine.2023.04.042","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T15:35:24Z","timestamp":1682350524000},"page":"3367-3379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Extending the range of Plasmodium falciparum transmission blocking antibodies"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4041-6775","authenticated-orcid":false,"given":"Lacy M.","family":"Simons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0392-1468","authenticated-orcid":false,"given":"Patricia","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nita","family":"Gombakomba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3291-8276","authenticated-orcid":false,"given":"Knashka","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2426-795X","authenticated-orcid":false,"given":"Raul","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3041-5402","authenticated-orcid":false,"given":"David L.","family":"Narum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4195-8835","authenticated-orcid":false,"given":"Gaspar","family":"Canepa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Festus","family":"Acquah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-8489","authenticated-orcid":false,"given":"Linda","family":"Amoah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick E.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4039-6199","authenticated-orcid":false,"given":"Carolina","family":"Barillas-Mury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shwu-Maan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-8473","authenticated-orcid":false,"given":"Emily","family":"Locke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-2432","authenticated-orcid":false,"given":"Kazutoyo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2749-4082","authenticated-orcid":false,"given":"Kim C.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.04.042_b0005","doi-asserted-by":"crossref","first-page":"21380","DOI":"10.1038\/s41598-021-00973-5","article-title":"Persistent Plasmodium falciparum infections enhance transmission-reducing immunity development","volume":"11","author":"Ayanful-Torgby","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.04.042_b0010","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/cid\/ciac527","article-title":"Malaria Transmission Dynamics in High Transmission Setting of Western Kenya and the Inadequate Treatment Response to Artemether-lumefantrine in an Asymptomatic Population","volume":"76","author":"Andagalu","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.042_b0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/infdis\/jiv370","article-title":"Dynamics of the Human Infectious Reservoir for Malaria Determined by Mosquito Feeding Assays and Ultrasensitive Malaria Diagnosis in Burkina Faso","volume":"213","author":"Ouedraogo","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.042_b0020","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/s41467-017-01270-4","article-title":"Examining the human infectious reservoir for Plasmodium falciparum malaria in areas of differing transmission intensity","volume":"8","author":"Goncalves","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.04.042_b0025","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/infdis\/jiac169","article-title":"Asymptomatic school-aged children are important drivers of malaria transmission in a high endemicity setting in Uganda","volume":"226","author":"Rek","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.042_b0030","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156588","article-title":"RTS, S: the first malaria vaccine","volume":"132","author":"Zavala","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2023.04.042_b0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS, S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"RTS","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.04.042_b0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","article-title":"Spread of artemisinin resistance in Plasmodium falciparum malaria","volume":"371","author":"Ashley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.04.042_b0045","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1086\/587645","article-title":"Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria","volume":"197","author":"Barnes","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.042_b0050","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1084\/jem.158.3.976","article-title":"Target antigens of transmission-blocking immunity on gametes of Plasmodium falciparum","volume":"158","author":"Rener","year":"1983","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2023.04.042_b0055","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1084\/jem.162.5.1460","article-title":"Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito","volume":"162","author":"Vermeulen","year":"1985","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2023.04.042_b0060","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.4049\/jimmunol.139.12.4213","article-title":"The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies","volume":"139","author":"Quakyi","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0065","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.22-0023","article-title":"Transmission-Blocking Vaccines: From Conceptualization to Realization","author":"Miller","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2023.04.042_b0070","article-title":"Transmission-Blocking Vaccines: Old Friends and New Prospects","volume":"8787","author":"Acquah","year":"2019","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.04.042_b0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-3024.1987.tb00511.x","article-title":"Target antigens of malaria transmission blocking immunity exist as a stable membrane bound complex","volume":"9","author":"Kumar","year":"1987","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0080","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/333074a0","article-title":"A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains","volume":"333","author":"Kaslow","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.04.042_b0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0166-6851(93)90158-T","article-title":"Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48\/45 of Plasmodium falciparum","volume":"61","author":"Kocken","year":"1993","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0090","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1365-2958.2006.05284.x","article-title":"Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production","volume":"61","author":"Eksi","year":"2006","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0166-6851(02)00091-9","article-title":"Male-specific expression of the paralog of malaria transmission-blocking target antigen Pfs230, PfB0400w","volume":"122","author":"Eksi","year":"2002","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0100","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1126\/science.282.5391.1126","article-title":"Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum","volume":"282","author":"Gardner","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.04.042_b0105","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.molbiopara.2006.05.015","article-title":"Pfs47, paralog of the male fertility factor Pfs48\/45, is a female specific surface protein in Plasmodium falciparum","volume":"149","author":"van Schaijk","year":"2006","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0110","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1128\/iai.65.3.1109-1113.1997","article-title":"A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines","volume":"65","author":"Duffy","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.04.042_b0115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-018-0065-5","article-title":"Antibody targeting of a specific region of Pfs47 blocks Plasmodium falciparum malaria transmission","volume":"3","author":"Canepa","year":"2018","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.04.042_b0120","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1128\/IAI.01056-13","article-title":"Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay","volume":"81","author":"Miura","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.04.042_b0125","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1101\/gad.1656508","article-title":"The conserved plant sterility gene HAP2 functions after attachment of fusogenic membranes in Chlamydomonas and Plasmodium gametes","volume":"22","author":"Liu","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.vaccine.2023.04.042_b0130","doi-asserted-by":"crossref","first-page":"eabg2112","DOI":"10.1126\/scitranslmed.abg2112","article-title":"Plasmodium falciparum Pf77 and male development gene 1 as vaccine antigens that induce potent transmission-reducing antibodies","volume":"13","author":"Tripathi","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2023.04.042_b0135","doi-asserted-by":"crossref","first-page":"13461","DOI":"10.1073\/pnas.0702239104","article-title":"Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen","volume":"104","author":"Dinglasan","year":"2007","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.vaccine.2023.04.042_b0140","doi-asserted-by":"crossref","unstructured":"Kaslow D.C. Efforts to Develop Pfs25 Vaccines. Am J Trop Med Hyg 2022; doi: 10.4269\/ajtmh.21-1326.","DOI":"10.4269\/ajtmh.21-1326"},{"key":"10.1016\/j.vaccine.2023.04.042_b0145","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/S0264-410X(02)00701-6","article-title":"Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials","volume":"21","author":"Zou","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.042_b0150","doi-asserted-by":"crossref","first-page":"19913","DOI":"10.1074\/jbc.M116.732305","article-title":"Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230","volume":"291","author":"MacDonald","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2023.04.042_b0155","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.21-1337","article-title":"The Virtues and Vices of Pfs230: From Vaccine Concept to Vaccine Candidate","author":"Duffy","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2023.04.042_b0160","article-title":"A Reproducible and Scalable Process for Manufacturing a Pfs48\/45 Based Plasmodium falciparum Transmission-Blocking Vaccine","volume":"11","author":"Singh","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0165","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.21-1320","article-title":"40 Years of Pfs48\/45 Research as a Transmission-Blocking Vaccine Target of Plasmodium falciparum Malaria","author":"Sauerwein","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2023.04.042_b0170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/14760584.2021.1878028","article-title":"Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination","volume":"20","author":"Duffy","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2023.04.042_b0175","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.21-1325","article-title":"Pfs47 as a Malaria Transmission-Blocking Vaccine Target","author":"Molina-Cruz","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2023.04.042_b0180","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146221","article-title":"Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice","volume":"131","author":"Healy","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2023.04.042_b0185","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41541-020-0196-3","article-title":"Malaria vaccines since 2000: progress, priorities, products","volume":"5","author":"Duffy","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.04.042_b0190","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1038\/s41467-019-11980-6","article-title":"Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25","volume":"10","author":"McLeod","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.04.042_b0195","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/s41467-017-01924-3","article-title":"Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25","volume":"8","author":"Scally","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.04.042_b0200","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1107\/S0907444994001782","article-title":"Crystallization of an intact monoclonal antibody (4B7) against Plasmodium falciparum malaria with peptides from the Pfs25 protein antigen","volume":"50","author":"Stura","year":"1994","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.vaccine.2023.04.042_b0205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0166-6851(96)02621-7","article-title":"Stage-specific processing of Pfs230, a Plasmodium falciparum transmission-blocking vaccine candidate","volume":"78","author":"Williamson","year":"1996","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0210","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1365-3024.1999.00255.x","article-title":"Immunogenicity of malaria transmission-blocking vaccine candidate, y230.CA14 following crosslinking in the presence of tetanus toroid","volume":"21","author":"Vincent","year":"1999","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0215","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/s41467-021-21955-1","article-title":"A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes","volume":"12","author":"Coelho","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.04.042_b0220","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s42003-020-01123-9","article-title":"Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48\/45 proteins","volume":"3","author":"Singh","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0225","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.immuni.2023.01.012","article-title":"A human antibody epitope map of Pfs230D1 derived from analysis of individuals vaccinated with a malaria transmission-blocking vaccine","volume":"56","author":"Tang","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2023.04.042_b0230","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41467-017-02646-2","article-title":"Unravelling the immune signature of Plasmodium falciparum transmission-reducing immunity","volume":"9","author":"Stone","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.04.042_b0235","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.174.5.1203","article-title":"Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals","volume":"174","author":"Barr","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2023.04.042_b0240","doi-asserted-by":"crossref","first-page":"e57909","DOI":"10.1371\/journal.pone.0057909","article-title":"Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays","volume":"8","author":"Miura","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.04.042_b0245","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12936-017-1955-0","article-title":"Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48\/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana","volume":"16","author":"Acquah","year":"2017","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2023.04.042_b0250","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-3024.1994.tb00305.x","article-title":"Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement-fixing","volume":"16","author":"Read","year":"1994","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0255","doi-asserted-by":"crossref","first-page":"9533","DOI":"10.1073\/pnas.88.21.9533","article-title":"Identification of a continuous and cross-reacting epitope for Plasmodium falciparum transmission-blocking immunity","volume":"88","author":"Wizel","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.04.042_b0260","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1186\/1471-2164-12-587","article-title":"Directional gene expression and antisense transcripts in sexual and asexual stages of Plasmodium falciparum","volume":"12","author":"Lopez-Barragan","year":"2011","journal-title":"BMC Genomics"},{"key":"10.1016\/j.vaccine.2023.04.042_b0265","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1046\/j.1365-2958.2002.02986.x","article-title":"Targeting and sequestration of truncated Pfs230 in an intraerythrocytic compartment during Plasmodium falciparum gametocytogenesis","volume":"44","author":"Eksi","year":"2002","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0270","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijpara.2016.10.002","article-title":"The s48\/45 six-cysteine proteins: mediators of interaction throughout the Plasmodium life cycle","volume":"47","author":"Arredondo","year":"2017","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0275","doi-asserted-by":"crossref","first-page":"12805","DOI":"10.1074\/jbc.M113.455667","article-title":"Structural and biochemical characterization of Plasmodium falciparum 12 (Pf12) reveals a unique interdomain organization and the potential for an antiparallel arrangement with Pf41","volume":"288","author":"Tonkin","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2023.04.042_b0280","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1038\/s41467-018-06340-9","article-title":"Structural basis for recognition of the malaria vaccine candidate Pfs48\/45 by a transmission blocking antibody","volume":"9","author":"Lennartz","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.04.042_b0285","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1038\/s41467-018-06742-9","article-title":"Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48\/45","volume":"9","author":"Kundu","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.04.042_b0290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0166-6851(95)02507-3","article-title":"Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes","volume":"75","author":"Williamson","year":"1995","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0295","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.vaccine.2019.02.021","article-title":"Identification of domains within Pfs230 that elicit transmission blocking antibody responses","volume":"37","author":"Tachibana","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.042_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.945924","article-title":"Plasmodium 6-Cysteine Proteins: Functional Diversity, Transmission-Blocking Antibodies and Structural Scaffolds","volume":"12","author":"Lyons","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.774537","article-title":"Characterization of Naturally Acquired Immunity to a Panel of Antigens Expressed in Mature P. falciparum Gametocytes","volume":"11","author":"Muthui","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2023.04.042_b0310","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1016\/j.vaccine.2009.06.069","article-title":"Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro","volume":"27","author":"Blagborough","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.042_b0315","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0166-6851(92)90173-H","article-title":"Alpha-tubulin II is a male-specific protein in Plasmodium falciparum","volume":"56","author":"Rawlings","year":"1992","journal-title":"Mol Biochem Parasitol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2300453X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2300453X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:18:41Z","timestamp":1777537121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2300453X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":63,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0264410X2300453X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.042","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extending the range of Plasmodium falciparum transmission blocking antibodies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}